Todays Report: The Zacks Investment Research Upgrades Vascular Solutions Inc. (VASC) to Buy

The Zacks Investment Research Upgrades Vascular Solutions Inc. (VASC) to Buy

Vascular Solutions Inc. (NASDAQ:VASC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday. The brokerage presently has a $52.00 price objective on the medical device company’s stock. Zacks Investment Research’s price target points to a potential upside of 14.11% from the company’s previous close.

According to Zacks, “Vascular Solutions Inc. manufactures, markets and sells the Vascular Solutions Duett sealing device, which enables cardiologists and radiologists to rapidly seal the puncture site following catheterization procedures such as angiography, angioplasty and stenting. Its product combines a simple balloon catheter delivery mechanism with a powerful, proprietary procoagulant. The company believes its product offers advantages over both manual compression and the three other FDA-approved devices used to seal the puncture site following the catheterization. “

Several other research firms also recently issued reports on VASC. Canaccord Genuity set a $53.00 price target on shares of Vascular Solutions and gave the company a “buy” rating in a research report on Tuesday, October 25th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 price target on shares of Vascular Solutions in a research report on Wednesday, October 26th. TheStreet raised shares of Vascular Solutions from a “hold” rating to a “buy” rating in a research report on Monday, July 25th. Sidoti downgraded shares of Vascular Solutions from a “buy” rating to a “neutral” rating and set a $47.00 price target for the company. in a research report on Tuesday, July 12th. Finally, Piper Jaffray Cos. lifted their price target on shares of Vascular Solutions from $45.00 to $49.00 and gave the company an “overweight” rating in a research report on Tuesday, July 26th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $51.80.

Vascular Solutions (NASDAQ:VASC) opened at 45.57 on Thursday. The company has a market capitalization of $798.98 million, a price-to-earnings ratio of 66.24 and a beta of 0.54. The stock has a 50 day moving average of $47.83 and a 200 day moving average of $43.11. Vascular Solutions has a 12 month low of $24.34 and a 12 month high of $50.72.

Vascular Solutions (NASDAQ:VASC) last released its quarterly earnings data on Monday, October 24th. The medical device company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.01. The company earned $41.80 million during the quarter. Vascular Solutions had a net margin of 7.57% and a return on equity of 16.14%. The business’s revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.27 EPS. Equities analysts anticipate that Vascular Solutions will post $1.24 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of VASC. Mason Street Advisors LLC purchased a new position in Vascular Solutions during the second quarter worth about $141,000. Bank of Montreal Can purchased a new position in Vascular Solutions during the second quarter worth about $202,000. First Mercantile Trust Co. increased its position in Vascular Solutions by 129.4% in the third quarter. First Mercantile Trust Co. now owns 4,242 shares of the medical device company’s stock worth $205,000 after buying an additional 2,393 shares in the last quarter. Barclays PLC purchased a new position in Vascular Solutions during the second quarter worth about $213,000. Finally, JPMorgan Chase & Co. increased its position in Vascular Solutions by 37.0% in the second quarter. JPMorgan Chase & Co. now owns 5,131 shares of the medical device company’s stock worth $214,000 after buying an additional 1,387 shares in the last quarter. 80.94% of the stock is currently owned by hedge funds and other institutional investors.

Vascular Solutions Company Profile

Vascular Solutions, Inc is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world.

Related posts

Leave a Comment